pLC-HA active Nedd8-P2A-Hygro
(Plasmid
#124307)
-
PurposeLentiviral vector for expression of HA tagged active or C-terminal cleaved Nedd8-P2A-Hygro casette from a CMV promoter
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 124307 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepLCE
- Total vector size (bp) 7803
-
Vector typeMammalian Expression, Lentiviral
-
Selectable markersHygromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameNedd8
-
SpeciesH. sapiens (human)
-
Insert Size (bp)225
-
MutationFive C-terminal amino acids missing compared to wild-type Nedd8. The cleaved form represents the active form of Nedd8.
-
Entrez GeneNEDD8 (a.k.a. NEDD-8)
- Promoter CMV
-
Tag
/ Fusion Protein
- HA (N terminal on insert)
Cloning Information
- Cloning method Gibson Cloning
- 5′ sequencing primer -
- 3′ sequencing primer - (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byNedd8 cDNA from Addgene plasmid 18711 was used as a template for PCR amplification and subsequent mutagenesis.
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pLC-HA active Nedd8-P2A-Hygro was a gift from Eva Gottwein (Addgene plasmid # 124307 ; http://n2t.net/addgene:124307 ; RRID:Addgene_124307) -
For your References section:
Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma. Patil A, Manzano M, Gottwein E. Blood Adv. 2019 Jul 23;3(14):2105-2117. doi: 10.1182/bloodadvances.2019031732. 10.1182/bloodadvances.2019031732 PubMed 31300418